Related references
Note: Only part of the references are listed.Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Maria-Victoria Mateos et al.
BLOOD (2012)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
The Era of Combination Therapy in Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Kenneth C. Anderson
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L. Wolf et al.
LEUKEMIA & LYMPHOMA (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Philippe Moreau et al.
BLOOD (2011)
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J. Morgan et al.
BLOOD (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Approach to the treatment of multiple myeloma: a clash of philosophies
S. Vincent Rajkumar et al.
BLOOD (2011)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay et al.
BLOOD (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Adrian Alegre et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (< 12 months)
Christopher P. Venner et al.
LEUKEMIA & LYMPHOMA (2011)
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial
Dominik Dytfeld et al.
LEUKEMIA & LYMPHOMA (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
Dianne Pulte et al.
ONCOLOGIST (2011)
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Shaji Kumar
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Jean-Luc Harousseau et al.
BLOOD (2010)
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
Morie A. Gertz et al.
BLOOD (2010)
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
Bijay Nair et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
CR represents an early index of potential long survival in multiple myeloma
M. Wang et al.
BONE MARROW TRANSPLANTATION (2010)
Multiple myeloma - current issues and controversies
Shaji Kumar
CANCER TREATMENT REVIEWS (2010)
Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study
Tiina M. Oivanen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma
Mervi Putkonen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Jean-Luc Harousseau et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
Heinz Ludwig et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Pierre Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Ultra High-Risk Myeloma
Herve Avet-Loiseau
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Predicting durable remissions following thalidomide therapy for relapsed myeloma
Hang Quach et al.
LEUKEMIA & LYMPHOMA (2009)
Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse
Marta Krejci et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A. Palumbo et al.
ANNALS OF ONCOLOGY (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
Ruben Niesvizky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction:: the prognostic impact of achieving molecular response
Pilar Martinez-Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
Bart Barlogie et al.
CANCER (2008)
Stem-cell transplantation for multiple myeloma in the era of novel drugs
William Bensinger
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Endpoints for assessing drug activity in clinical trials
Richard Pazdur
ONCOLOGIST (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler et al.
CLINICAL CANCER RESEARCH (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelorna
Massimo Offidani et al.
BLOOD (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma
Mohamad A. Hussein et al.
MAYO CLINIC PROCEEDINGS (2006)
Complete response in multiple myeloma - Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
RA Kyle et al.
CANCER (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Early response to therapy and survival in multiple myeloma
CG Schaar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials
BGM Durie et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol
A Riccardi et al.
EUROPEAN JOURNAL OF CANCER (2003)
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
S Singhal et al.
BONE MARROW TRANSPLANTATION (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma
FE Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Effect of complete response on outcome following autologous stem cell transplantation for myeloma
SV Rajkumar et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
